Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CNTB

Connect Biopharma Holdings Ltd ADR

Dec 12 • 12:24PM ET

1.15

Dollar change -0.08
Percentage change -6.50	%

Healthcare • Biotechnology • China • NASD

Peers: VRTX REGN GILD BIIB AMGN NBIX BMRN INCY SRPT EXEL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	3.62%	Shs Outstand	55.25M	Perf Week	15.00%
Market Cap	63.54M	Forward P/E	-	EPS next Y	0.00	Insider Trans	0.00%	Shs Float	53.25M	Perf Month	10.58%
Income	-	PEG	-	EPS next Q	-0.33	Inst Own	5.33%	Short Float	0.11%	Perf Quarter	-6.50%
Sales	-	P/S	-	EPS this Y	81.80%	Inst Trans	28.35%	Short Ratio	2.13	Perf Half Y	-31.55%
Book/sh	2.00	P/B	0.58	EPS next Y	100.00%	ROA	-	Short Interest	0.06M	Perf Year	40.59%
Cash/sh	1.99	P/C	0.58	EPS next 5Y	-	ROE	-	52W Range	0.68 - 2.66	Perf YTD	-2.54%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.81%	ROI	-	52W High	-56.77%	Beta	-0.34
Dividend TTM	-	Quick Ratio	12.04	Sales past 5Y	0.00%	Gross Margin	-	52W Low	69.69%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	12.04	EPS Y/Y TTM	27.23%	Oper. Margin	-	RSI (14)	53.54	Volatility	11.18% 9.77%
Employees	81	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	7.83
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	113.37%	Payout	-	Rel Volume	1.69	Prev Close	1.23
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Sep 05 AMC	Avg Volume	26.90K	Price	1.15
SMA20	8.57%	SMA50	-0.59%	SMA200	-14.61%	Trades		Volume	21,484	Change	-6.50%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-24	Initiated	H.C. Wainwright	Buy	$7
Apr-13-21	Initiated	SVB Leerink	Outperform	$32
Apr-13-21	Initiated	Piper Sandler	Overweight
Apr-13-21	Initiated	Jefferies	Buy	$27

Oct-15-24 07:30AM	Attovia Therapeutics Appoints Chief Financial Officer (GlobeNewswire) -10.00%
Sep-10-24 08:00AM	Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024 (GlobeNewswire)
Sep-05-24 04:05PM	Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update (GlobeNewswire) -7.76% +5.05%
Jul-01-24 08:00AM	Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum (GlobeNewswire) -5.26%
Jun-12-24 06:03PM	Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.08%
04:15PM	Loading…
04:15PM	Connect Biopharma Announces New Leadership and Chair of the Board of Directors (GlobeNewswire)
May-22-24 04:05PM	Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma (GlobeNewswire) -5.08% +7.14%
May-07-24 06:30AM	Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma (GlobeNewswire)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile) +8.39%
Apr-16-24 04:05PM	Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -10.40%
Mar-19-24 08:30AM	Connect Biopharma to Participate in H.C. Wainwright 2 Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire)
Feb-12-24 04:30PM	Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors (GlobeNewswire) -8.93%
Dec-12-23 06:00AM	Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma (GlobeNewswire) -9.11%
Dec-11-23 04:05PM	Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023 (GlobeNewswire)
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile) +13.86%
09:40AM	Loading…
Nov-28-23 09:40AM	Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year? (Zacks) -8.93%
Nov-21-23 07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -38.83%
06:03AM	Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China (GlobeNewswire)
06:00AM	Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Nov-20-23 04:41PM	Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023 (GlobeNewswire)
Nov-06-23 09:40AM	Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year? (Zacks) +6.62%
Oct-20-23 09:40AM	Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year? (Zacks) -7.63%
Sep-15-23 12:00PM	Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -9.51%
Sep-12-23 04:15PM	Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update (GlobeNewswire)
06:00AM	Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire)
Aug-24-23 06:21PM	Connect Biopharma to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Jul-10-23 08:00AM	Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology (GlobeNewswire)
Jul-05-23 04:05PM	Connect Biopharma to Participate in the SVB Securities Therapeutics Forum (GlobeNewswire)
Jun-01-23 04:05PM	Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis (GlobeNewswire) +9.91%
Apr-11-23 04:05PM	Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.56%
09:24AM	Loading…
Mar-20-23 09:24AM	Connect Biopharma's Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement Across All Body Regions (Benzinga) +20.00%
Mar-18-23 02:40PM	Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms (Business Wire)
Mar-17-23 04:38PM	Connect Biopharma stock up more than 40% after trial data (MarketWatch) +20.00%
04:05PM	Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions (Business Wire)
Mar-06-23 08:15AM	Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Feb-06-23 08:30AM	Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California (GlobeNewswire)
Jan-16-23 05:13AM	Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth? (Simply Wall St.)
Dec-30-22 07:30AM	Connect Biopharma Provides Business and Clinical Development Program Update (GlobeNewswire) +11.06%
Dec-19-22 08:00AM	Connect Biopharma to Present at the San Francisco Biotech Showcase in January (GlobeNewswire)
Dec-02-22 05:00PM	Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) -5.40%
Oct-27-22 04:05PM	Connect Biopharma To Present at Upcoming Investor and Scientific Conferences (GlobeNewswire)
Oct-04-22 11:40AM	Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients (Benzinga) -15.27%
08:56AM	CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China (GlobeNewswire)
07:00AM	Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China (GlobeNewswire)
Oct-03-22 04:10PM	Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Sep-13-22 04:30PM	Edited Transcript of CNTB.OQ earnings conference call or presentation 13-Sep-22 8:30pm GMT (Thomson Reuters StreetEvents)
04:05PM	Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update (GlobeNewswire)
Sep-01-22 08:00AM	Connect Biopharma to Report First Half 2022 Financial Results on September 13 (GlobeNewswire)
Aug-30-22 09:36AM	Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile (Benzinga)
08:00AM	Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study (GlobeNewswire)
Aug-08-22 12:19PM	Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth? (Simply Wall St.) +23.48%
Jul-12-22 06:02AM	Connect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This Year (Benzinga) +5.34%
Jul-11-22 04:05PM	Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022 (GlobeNewswire)
Jun-17-22 04:05PM	Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement (GlobeNewswire) +8.29% +8.18%
Jun-08-22 12:00PM	All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy (Zacks)
Jun-02-22 04:05PM	Connect Biopharma to Participate at the Jefferies Healthcare Conference (GlobeNewswire)
May-17-22 04:05PM	Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual Conference (GlobeNewswire)
May-04-22 07:43AM	Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study (Benzinga) -57.72%
May-03-22 04:05PM	Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
May-02-22 02:02PM	What Kind Of Investors Own Most Of Connect Biopharma Holdings Limited (NASDAQ:CNTB)? (Simply Wall St.) -8.37%
Mar-31-22 04:05PM	Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire)
Mar-01-22 08:00AM	Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer (GlobeNewswire) +5.10%
05:06AM	Here's Why We're Not Too Worried About Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Situation (Simply Wall St.)
Feb-09-22 07:00AM	Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire)
Jan-24-22 07:00AM	Connect Biopharma Presents Data and Analyses from the Global Phase 2b Trial of CBP-201 at the Maui Derm Conference (GlobeNewswire) -6.33%
Jan-05-22 07:00AM	Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire) -12.28%
Jan-04-22 04:05PM	Connect Biopharma to Host Conference Call on January 5 at 8:30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201 (GlobeNewswire)
Dec-25-21 02:38AM	Federated Hermes Prudent Bear Fund Buys PowerShares QQQ Trust Ser 1, iShares Russell 2000 ETF, ... (GuruFocus.com)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-22-21 08:00AM	Connect Biopharma Expands Executive Leadership Team with Hire of Chief Financial Officer (GlobeNewswire) -8.40%
04:53AM	52 Biggest Movers From Friday (Benzinga)
Nov-19-21 02:47PM	Mid-Afternoon Market Update: Dow Falls 200 Points; Connect Biopharma Shares Tumble (Benzinga) -57.72%
12:00PM	33 Stocks Moving In Friday's Mid-Day Session (Benzinga)
11:57AM	Why Connect Biopharma Stock Is Crashing Today (Motley Fool)
08:00AM	Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial in Moderate-to-Severe Ulcerative Colitis (GlobeNewswire)
07:19AM	Connect Biopharma's Mid-Stage Atopic Dermatitis Trial Meets Primary Endpoint (Benzinga)
Nov-18-21 04:02PM	Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Nov-11-21 08:00AM	Connect Biopharma to Participate at Upcoming Conferences (GlobeNewswire)
Oct-19-21 08:00AM	Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit (GlobeNewswire) +7.72%
Sep-08-21 08:00AM	Connect Biopharma Announces First Subject Dosed in Phase 2 Trial Evaluating CBP-201 in Adult Patients with Chronic Rhinosinusitis with Nasal Polyps (GlobeNewswire)
Sep-02-21 08:00AM	Connect Biopharma Announces First Patient Dosed in China Pivotal Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
07:55AM	Here's Why We're Not Too Worried About Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn Situation (Simply Wall St.)
Aug-31-21 04:05PM	Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results (GlobeNewswire) +13.66%
Aug-25-21 08:00AM	Connect Biopharma to Host First Half 2021 Financial Results Conference Call on September 1, 2021 (GlobeNewswire) -8.31%
Aug-23-21 04:05PM	Connect Biopharma Hires General Counsel & Chief Compliance Officer and Appoints a New Board Member (GlobeNewswire)
Jun-11-21 03:57PM	MDC Partners, Connect Biopharma See Activist Action (Barrons.com)
May-26-21 08:00AM	Connect Biopharma to Participate at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-25-21 08:00AM	Connect Biopharma Announces First Subject Dosed in Phase I Trial Evaluating Safety, Tolerability and Pharmacokinetic Profile of CBP-174 in Healthy Adult Subjects (GlobeNewswire) -6.15%
May-12-21 08:00AM	Connect Biopharma Announces First Patient Dosed in Phase 2 Trial Evaluating CBP-201 in Adults with Moderate-to-Severe Persistent Asthma (GlobeNewswire) +6.72%
Apr-08-21 08:00AM	Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2 Clinical Trial in Moderate-to-Severe Atopic Dermatitis (GlobeNewswire)
Mar-23-21 04:05PM	Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire) -9.89% -5.01%
Mar-18-21 11:58PM	Connect Biopharma Holdings Limited announces pricing of Initial Public Offering (GlobeNewswire)

Connect Biopharma Holdings Ltd. engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in Taicang, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CNTB

Connect Biopharma Holdings Ltd ADR

Upgrade your FINVIZ experience